ILC Therapeutics

🚀 𝗔𝗹𝗳𝗮𝗰𝘆𝘁𝗲™ - 𝗼𝘂𝗿 𝗹𝗲𝗮𝗱 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 🚀 💡 Our lead hybrid interferon candidate Alfacyte™, is being developed as a broad-spectrum antiviral for the treatment of upper respiratory tract infections. 🦠 Alfacyte is a promising novel therapeutic to tackle the threat of future #pandemics, including #coronaviruses. 🔬 Alfacyte™ has demonstrated activity against multiple viruses and we are progressing towards the clinic as a treatment for respiratory syncytial virus (RSV). 🔗 Find out more on our website www.ilctherapeutics.com.   #Alfacyte #Biotech #Innovation #Antiviral #RSV

🚀 𝗙𝗶𝗿𝘀𝘁-𝗶𝗻-𝗰𝗹𝗮𝘀𝘀 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 🚀 Our 𝗵𝘆𝗯𝗿𝗶𝗱 𝗶𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗼𝗻 technology platform is delivering a pipeline of novel pleiotropic drug candidates engineered for reduced toxicity and improved efficacy. 🥇 𝗙𝗶𝗿𝘀𝘁-𝗶𝗻-𝗰𝗹𝗮𝘀𝘀: Our platform can rationally design, select and develop novel hybrid interferon candidates, engineering highly specific proteins with multiple favourable attributes from natural IFNs. 🌌 𝗛𝘆𝗯𝗿𝗶𝗱 𝗶𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗼𝗻𝘀 have the potential to act on multiple targets and to modulate multiple avenues in disease. This gives them a broader spectrum of activity compared with other drug classes such as monoclonal antibodies or small molecules.   🔗 Find out more on our website www.ilctherapeutics.com #Biotech #HybridInterferons #DrugDevelopment #Healthcare

🌟 𝗛𝘆𝗯𝗿𝗶𝗱 𝗶𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗼𝗻𝘀 – 𝗮𝗻 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄 𝗱𝗿𝘂𝗴 𝗰𝗹𝗮𝘀𝘀 🌟 Our 𝗵𝘆𝗯𝗿𝗶𝗱 𝗶𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗼𝗻𝘀 are a new engineered drug class, designed to have improved therapeutic profiles and broad applications across multiple disease areas. 🔍 𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝗜𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗼𝗻𝘀? As essential modulators of the immune system, interferons are among the body’s first and most powerful defences against viral, bacterial and fungal pathogens. While natural interferons have been used effectively in the clinic for nearly 40 years, our 𝗵𝘆𝗯𝗿𝗶𝗱 𝗶𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗼𝗻𝘀 are highly distinct and offer a number of advantages. 💡 By building on our knowledge of natural IFNs, we have combined favourable attributes of specific interferon sub-types to develop novel drug candidates designed to deliver: ✅ 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆  ✅ 𝗜𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆  ✅ 𝗕𝗿𝗼𝗮𝗱-𝘀𝗽𝗲𝗰𝘁𝗿𝘂𝗺 𝗮𝗻𝘁𝗶𝘃𝗶𝗿𝗮𝗹 & 𝗮𝗻𝘁𝗶-𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 Find out more on our website: www.ilctherapeutics.com. #Biotech #Immunotherapy #HybridInterferons #DrugDevelopment 

🎙️ In Case You Missed It: Earlier this year, prior to our most recent fundraise, our Chair Peter Bains and now CEO, Owain Millington, discussed the Company’s hybrid interferon platform technology, the renewed industry interest in infectious disease and the pros and cons of running a startup biotech in the UK with Lucie Ellis-Taitt during the In Vivo Podcast (Pharma Intelligence, now Citeline ). 🔗 Please check here to listen: https://lnkd.in/eaKfuJWE. 

𝗦𝗲𝗻𝗶𝗼𝗿 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 Dr Dawn Firmin, Chief Operating Officer Dawn has over 15 years’ experience in drug development, with significant expertise in managing and coordinating the different phases of the drug development process, having held key roles in early-stage companies, including MGB Biopharma and EnteroBiotix.

𝗦𝗲𝗻𝗶𝗼𝗿 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 Julie Bailey, CFO Julie is a certified and chartered accountant who has worked for over two decades in executive finance roles, where she led multiple successful raises and exits. She was recently appointed full-time CFO after joining ILCT as a consultant in 2023.

𝗦𝗲𝗻𝗶𝗼𝗿 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 Dr Owain Millington, CEO Owain has over 20 years’ experience in the immunology space, working in early-stage companies including TC BioPharm, Medisix and Matterhorn Biosciences. He has strong experience in building and leading Discovery and Development teams, successfully identifying new candidates and delivering immunotherapy products into the clinic. 

Today we announced the completion of a £2.5m fundraise led by Eos, Scottish Enterprise, Medical Incubator Japan K.K. and Robert Kopple, that will support the continued pre-clinical development of our two lead assets, Alfacyte™ and Dermacyte™ as they move towards the clinic. Along with the funding we were delighted to announce the appointments of Owain Millington as Chief Executive Officer, Julie Bailey as Chief Financial Officer, and Dawn Firmin as Chief Operations Officer. https://lnkd.in/eaS_-_z2 #innovation #hybridinterferons